Purpose:
The Torcetrapib project was terminated on December 2, 2006 due to safety findings.
To demonstrate if torcetrapib/atorvastatin can reduce the risk for major cardiovascular
disease events, when compared to atorvastatin alone, in patients with coronary heart disease
or risk equivalents
Criteria:
Inclusion Criteria:
- Diagnosis of coronary heart disease or risk equivalents that place the patient at
high risk for cardiovascular disease events
Exclusion Criteria:
- Women who are pregnant or lactating, or planning to become pregnant.
- Subjects with a clinically indicated need for statin (HMG-CoA reductase inhibitor)
therapy other than atorvastatin or other concomitant therapy with known lipid
altering effects on LDL-C and HDL-C including fibrates and nicotinic acid
- Subjects taking any drugs known to be associated with an increased risk of myositis
in combination with HMG-CoA reductase inhibitors
- Subjects with any other medical condition or laboratory abnormality which could
affect subject safety, preclude evaluationof response, or render unlikely that the
subject would complete the study